Precision medicine, not limited medicine: Sustainable drug development builds on effective data use
Precision medicines display high efficacies against their target groups, but they still face the same problems as other drugs: high attrition rates during development, acquired resistance after launch and so on.
On top of that, because they target small patient subgroups, it is hard for pharmaceutical companies to offset the high price of bringing them to market.
This white paper examines how a data-driven approach using cross-disciplinary information could help to make medicines that are effective but not limited. Experts in data-driven drug development recognize that the information already exists but that the frameworks for leveraging it need to be built.
Read the full paper to see what the pillars of such a cross-disciplinary information framework should be and the potential impact on precision medicine.
Read the white paper.
To access the complimentary white paper 'Precision Medicine, not Limited Medicine: Sustainable Drug Development Builds on Effective Data Use', please fill in the form below.
Elsevier's R&D Solutions for Drug Discovery & Development
Drive successful early drug discovery by providing chemists the shortest path to relevant literature, patent information, valid compound properties, and experimental procedures.
Learn more about Reaxys
Contact a Reaxys expert
Reaxys Medicinal Chemistry
Achieve more efficient hit identification and lead optimization by providing chemists the shortest path to normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more about Reaxys Medicinal Chemistry
Contact a Reaxys Medicinal Chemistry expert